GlassScriptPhysician profile
Renato B Roman
NPI 1114979234
$5,879.22
in general payments reported to CMS, 2019-2025
29 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $578 · 2021: $673 · 2022: $1,193 · 2023: $1,049 · 2024: $667 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.62 |
| Education | $120.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,023.72 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $1,010.61 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $713.39 | 2019-2023 | Krystexxa |
| Amgen INC. | $539.14 | 2019-2023 | Tavneos |
| Calliditas Therapeutics US INC. | $449.18 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $314.97 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $291.34 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $275.30 | 2021-2024 | |
| Travere Therapeutics, INC. | $159.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $154.00 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $153.17 | 2021-2023 | Lupkynis |
| Nxstage Medical, INC. | $107.90 | 2024 | |
| Mallinckrodt Enterprises LLC | $103.34 | 2019 | |
| Fresenius USA Marketing, INC. | $73.39 | 2019-2024 | |
| Glaxosmithkline, LLC. | $70.13 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $65.10 | 2019-2021 | |
| Genentech USA, INC. | $56.96 | 2019-2025 | Gazyva |
| Opko Pharmaceuticals, LLC | $48.42 | 2023 | Rayaldee |
| Ardelyx, INC. | $41.60 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $34.84 | 2022 | |
| Cormedix INC. | $31.23 | 2024 | Defencath |
| Baxter Healthcare | $27.37 | 2021 | |
| Genzyme Corporation | $26.38 | 2022 | |
| Medtronic, INC. | $22.80 | 2025 | Symplicity G3 |
| Xeris Pharmaceuticals, INC. | $21.52 | 2023 | Keveyis |
| Alexion Pharmaceuticals, INC. | $17.90 | 2023 | Ultomiris |
| Ani Pharmaceuticals, INC. | $16.02 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $15.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renato Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.